{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:59:42Z","timestamp":1759694382906},"reference-count":4,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,11,22]],"date-time":"2005-11-22T00:00:00Z","timestamp":1132617600000},"content-version":"vor","delay-in-days":12135,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[1972,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A 52\u2010year\u2010old male was observed with the recent development of progressive systemic sclerosis (PSS). The most prominent symptoms of the PSS were circulatory, with pain in the digits, severe Raynaud's phenomenon and associated atrophic changes and ulcerations of the fingertips. Therapy with phenoxybenzamine was instituted in an attempt to improve digital blood flow. Rapid development of dry gangrene of several digits was observed over the following month. A possible association between phenoxybenzamine therapy and decreased digital circulation is discussed.<\/jats:p>","DOI":"10.1002\/art.1780150511","type":"journal-article","created":{"date-parts":[[2007,2,14]],"date-time":"2007-02-14T16:24:12Z","timestamp":1171470252000},"page":"535-539","source":"Crossref","is-referenced-by-count":4,"title":["Possible adverse effect of phenoxybenzamine therapy in a patient with progressive systemic sclerosis"],"prefix":"10.1002","volume":"15","author":[{"given":"Lewis P.","family":"Parker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bevra H.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Kirk","family":"Osterland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,11,22]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-72-1-17"},{"key":"e_1_2_1_3_2","first-page":"128","article-title":"Management of scleroderma","volume":"46","author":"Winkelmann RK","year":"1971","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_1_4_2","first-page":"550","volume-title":"The Pharmacological Basis of Therapeutics","author":"Nickerson M","year":"1970"},{"key":"e_1_2_1_5_2","first-page":"955","article-title":"The case against vasodilator drugs in occlusive vascular disease of the legs","volume":"2","author":"Gillespie JA","year":"1959","journal-title":"Lancet"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.1780150511","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.1780150511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T18:10:22Z","timestamp":1700763022000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.1780150511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1972,9]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1972,9]]}},"alternative-id":["10.1002\/art.1780150511"],"URL":"https:\/\/doi.org\/10.1002\/art.1780150511","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[1972,9]]}}}